Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

83
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant Frozen Elephant Trunk and Total Artificial Heart as a Bridge to Heart Transplantation.

Annals of thoracic surgery short reports·2025
Same author

Utilization of leadless pacemaker following orthotopic heart transplantation for complete heart block during index hospitalization.

HeartRhythm case reports·2025
Same author

Next Generation Development of Hybrid Continuous Flow Pediatric Total Artificial Heart Technology: Design-Build-Test.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2023
Same author

The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2023
Same author

Feasibility of Outpatient Hemodialysis for Patients With Total Artificial Heart: A Case Series.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2023
Same author

Positive donor blood cultures are not associated with worse heart transplant survival.

Clinical transplantation·2023
Same journal

Do Differences in Patient-Reported Outcome Measures for Robot-Assisted and Navigated Unicompartmental Knee Replacement Achieve Minimal Clinically Important Differences?

Surgical technology international·2025
Same journal

Clinical and Radiological Results of the Integrated Acetabular MUTARS® RS Cup System in the Revision of Geriatric Patients.

Surgical technology international·2025
Same journal

Does Robotic-Assisted Functional Knee Positioning Result in Better Functional Outcomes One Year After Surgery.

Surgical technology international·2025
Same journal

One-Year Clinical Outcomes Following Anterior Cruciate Ligament Reconstruction Augmented with a Reinforced Bioinductive Implant.

Surgical technology international·2025
Same journal

In-Office Skin Grafting for Lower Extremity Wounds.

Surgical technology international·2025
Same journal

Revision ACL Reconstruction with Hamstring Autograft from the Contralateral Leg With and Without Internal Brace: A Comparative Study.

Surgical technology international·2025
See all related articles

Related Experiment Video

Updated: Oct 31, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.6K

Total Artificial Heart Update.

Jack Copeland1, Steve Langford2, Joseph Giampietro2

  • 1Banner University Hospital, Tucson, AZ.

Surgical Technology International
|June 28, 2021
PubMed
Summary
This summary is machine-generated.

The SynCardia Total Artificial Heart (TAH) is an FDA-approved device for biventricular failure, supporting patients for up to six years. Experienced centers show high transplant rates and survival, aiding organ recovery.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.6K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.9K

Related Experiment Videos

Last Updated: Oct 31, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.6K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.6K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.9K

Area of Science:

  • Cardiovascular Surgery
  • Medical Devices
  • Transplantation Medicine

Background:

  • The SynCardia Total Artificial Heart (TAH) is the sole FDA-approved biventricular cardiac replacement for bridge to transplantation.
  • It has received the European Union CE mark and been implanted in approximately 2000 patients worldwide.

Purpose of the Study:

  • To provide a comprehensive review of the SynCardia TAH.
  • To cover its history, mechanical function, monitoring, implantation, patient selection, management, and outpatient use.
  • To review existing and contemporary outcome data from clinical studies and experienced centers.

Main Methods:

  • Review of historical data and FDA study outcomes.
  • Analysis of contemporary data from high-volume TAH centers.
  • Discussion of device mechanics, implantation procedures, and patient management protocols.

Main Results:

  • In experienced centers, 60-80% of TAH recipients undergo transplantation.
  • Over 80% of transplanted patients survive beyond one year.
  • The TAH supports patients with irreversible biventricular failure for up to 6 years, ensuring physiologic pulsatile flow and promoting organ recovery.

Conclusions:

  • The SynCardia TAH is a proven device for managing patients with end-stage biventricular failure.
  • It effectively bridges patients to transplantation, improving survival and facilitating organ perfusion.
  • The device offers a viable option for patients with rapidly decompensating or chronic cardiac failure.